ÂÜÀòÂÒÂ×

Dr. Versavel has 30 years of clinical development experience in neuropathic pain and multiple neurology and psychiatry indications across the areas of clinical pharmacology, early and late phase clinical trials, and support of marketed products. Through vZenium LLC, he has served as consulting CMO at Alzheon (ALZ-801 in Alzheimer’s disease); Senior Vice President Clinical Development at Quartet Medicine (BH4 modulators in neuropathic pain); Medical Director at Biogen (vixotrigine (BIIB074) in neuropathic pain); and CMO at NeuroBo Pharmaceuticals (Phase 3 program in diabetic neuropathic pain).

Prior to forming vZenium, Dr. Versavel held positions of increasing responsibility at Bayer AG in Germany (pharmaco-EEG and computerized cognition testing); Schering AG (betaferon in MS, AMPA antagonist in stroke); Parke-Davis in France (International Therapy Area Head for Neurology, Phase 3 international development of pregabalin (Lyrica) in epilepsy, neuropathic pain, and fibromyalgia); Pfizer (clinical leader for sumanirole in Parkinson’s Disease and restless legs syndrome, global clinical leader for ziprasidone in schizophrenia and bipolar disorder); Sepracor (eslicarbazepine acetate approval as Aptiom); Sunovion (VP Clinical Research and Medical Affairs CNS); and Zalicus (Vice President, Clinical Research, novel calcium channel modulators in neuropathic pain).